VPHM ViroPharma beats, excluding tax benefit, guides FY06 in line (21.30 )
Reports Q4 (Dec) earnings of $0.41 per share, excluding $0.76 tax benefit, $0.14 better than the Reuters Estimates consensus of $0.27; revenues rose 118.7% year/year to $40.5 mln vs the $36.8 mln consensus. Co issues in-line guidance for FY06, sees revs of $160-170 mln vs. $167.27 mln consensus.